4 Merger and Acquisitions Stock Stories for Tuesday Appraisal

Kimberly-Clark Corporation (NYSE: KMB): Current price $99.82

The company announced on Tuesday its purchase of the anesthesia business of Life-Tech, which is a medical device maker based in Texas. The acquisition is comprised of needles, catheters and accessories associated with peripheral nerve block procedures. The newly-bought assets will become part of Kimberly-Clark’s Health Care division and will be added to K-C Health Care’s ON-Q array of products. Other business units of Life-Tech are not included in this transaction, the financials of which were not divulged.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

KMB

Obagi Medical Products (NASDAQ: OMPI): Current price $22.87

Obagi’s board has received a letter from Merz Pharma Group which detailed its proposal to purchase all of the outstanding common stock of Obagi for $22 per share in cash. This offer represents a 58 percent premium to Obagi’s close on March 14, the last trading day prior to the disclosure on Obagi’s fourth quarter earnings call that the firm had engaged a financial advisor to help explore “all opportunities.”  Merz believes that its current offer is superior to that of Valeant Pharmaceuticals International, which was tendered a few days before.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

OMPI

Newcastle Investment Corp. (NYSE:NCT): Current price $11.04

On Tuesday, Newcastle said it has acquired from HSBC Finance Corporation a 30-percent equity interest in a consumer loan portfolio having an unpaid principal balance of $4.2 billion as of December 31, 2012. Newcastle invested along with Springleaf Finance, a Fortress affiliate who will also be responsible for servicing the loans, and Blackstone Tactical Opportunities Advisors. The total purchase price for the portfolio is roughly $3 billion.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

NCT

Optimer Pharmaceuticals (NASDAQ:OPTR): Current price $13.97

Two knowledgeable sources say that the antibiotics maker which is currently examining a sale, has drawn interest from drugmakers including GlaxoSmithKline and Astellas Pharma, causing the shares to jump the most in nearly five years. Optimer intends to fetch as much as $1 billion in a possible auction, according to the sources, who also divulged that the firm attracted interest from Cubist Pharmaceuticals  and AstraZeneca.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

OPTR

Investing Insights: Where Will Dell Go Next?

More Articles About:    

More from The Cheat Sheet